Cart
0
Get 20% Free Customization In This Report
By this report from - $3759

Immunoprotein Diagnostic Testing Market by Technology (Radioimmunoassay, Immunoturbidity Assay, Chemiluminescence Assay, Immunoprotein Electrophoresis, Enzyme-Based Immunoassay, and Immunofluorescence Assay), by Type (C - reactive Protein Diagnostic Test, Complement System Protein Diagnostic Test, Prealbumin Diagnostic Test, Haptoglobin Diagnostic Test, Immunoglobulin Diagnostic Test, and Free Light Chain Diagnostic Test), and by Application (Autoimmune Disease Testing, Infectious Disease Testing, Allergy Testing, Endocrine Testing, Oncology Testing, and Toxicology Testing) - Global Opportunity Analysis and Industry Forecast, 2016-2023

LI 17486
Pages: 199
Apr 2017 | 2133 Views
face gplus_n
Author's : Shubhangi Bawkar and Abha Thakur
Tables: 74
Charts: 54
twit_n pr_n

Immunoprotein Diagnostic Testing Market Overview:

Global Immunoprotein Diagnostic Testing Market was valued at $16,485 million in 2016 and is expected to garner $27,290 million by 2022, registering a CAGR of 7.4% during the forecast period 2017-2023. Immunoproteins are the proteins used as a target for immunological probes or therapies. Immunoprotein diagnostic testing is the procedure of diagnosing the level of immunoproteins in the body for the analysis of diseases related to specific protein such as immunoglobulin, pre-albumin, and others.

Immunoprotein diagnostic testing market

The key factors that drive the market growth include rise in incidence & prevalence of diseases such as cancer, cardiovascular diseases, infectious diseases, and others. In addition, the rise in healthcare expenditure and healthcare insurance are expected to fuel the market growth during the analysis period. However, shortage of experienced healthcare professionals and lack of awareness among the population restrict the growth.

Segment Review

Based on technology, the global immunoprotein diagnostic testing industry is categorized into radioimmunoassay, immunoturbidity assay, chemiluminescence assay, immunoprotein electrophoresis, enzyme-based immunoassay, immunofluorescence assay, and other technologies. Enzyme-based immunoassay held the highest market share and chemiluminescence is expected to grow with the highest growth rate during the forecast period. The growth of the enzyme-based immunoassay market is fueled by the expanding use of immunoassays in cancer, POC IVD testing, infectious disease testing, therapeutic drug level monitoring, and the introduction of novel biomarkers. Advantages of ELISA, such as long shelf life and ease of use, have increased their acceptance among academic and industrial sectors. Based on type, immunoglobulin diagnostic tests dominated the market in 2016 owing to the high usage of immunoglobulin diagnostic tests for protein level analysis. By application, infectious disease testing captured the highest market share in 2016, owing to the high incidence of infectious disease.

Geographic Review:

Geographically, the global market is segmented into North America, Europe, Asia-Pacific, and LAMEA. North America held the largest share of the market in 2016, followed by Europe. On the other hand, Asia is anticipated to be the fastest-growing regional segment during the analysis period. The key factors that drive the growth of this market include increase in pool of patient population, rise in prevalence of different types of diseases such as cancer & infectious diseases, and rise in government investments for development of better healthcare facilities and R&D. Asia-Pacific is expected to emerge as the area with maximum growth potential due to focus of key players in the emerging economies and improving healthcare infrastructure.

Increase in Geriatric Population and Surge in Incidence and Prevalence of Chronic Diseases

The geriatric population has significantly grown in the past few years. They are vulnerable to various chronic diseases such as cardiovascular diseases, cancer, type 2 diabetes, obesity, and arthritis. For instance, according to the estimates of American Heart Association (AHA), in 2016, approximately 17.3 million deaths per year resulted due to cardiovascular diseases, and are expected to be more than 23.6 million by 2030. Similarly, according to the report of World Health Organization (WHO) in 2017, cancer is the second leading cause of deaths worldwide. It accounted for 8.8 million deaths in 2015, and approximately 70% of deaths in low- and middle-income countries. Therefore, rise in prevalence of chronic diseases is expected to fuel the demand for diagnostic testing; thereby, driving the global immunoprotein diagnostics testing market.

Complex Regulatory Framework

Complexity in regulatory frameworks is expected to hamper the market growth. The introduction of novel technology in the market is affected by factors such as time-consuming approvals, high cost of review, and cumbersome maintenance. The results provided by immunoprotein diagnostic tests are used to determine the treatment module of patients; hence, accuracy and efficiency of these tests are of prime importance for appropriate diagnosis. The need for new regulatory policies is prevalent for resolving issues in the current system. In Europe, the IVD is currently regulated by “In Vitro Diagnostic Medical Devices Directive (Directive 98/79/EC).” This regulatory body has not implemented effective regulatory norms and new technology requirements in the IVD market.

Major companies operating in this market adopt product launch as their key development strategy. Companies profiled in this market include, Abbott Laboratories, Abcam PLC, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Enzo Life Sciences, Ortho Clinical Diagnostics, Roche Diagnostics, Siemens Healthcare, and Thermo Fisher Scientific.

The other players (the profiles of these players are not covered in the report) in the value chain include Affymetrix, Alere, bioMérieux, ORGENTEC Diagnostika, Sekisui Diagnostics, IBL International, ImmunoDX, Quidel Corporation, Trinity Biotech, and others.

Key Benefits:

  • The study provides an in-depth analysis of the immunoprotein diagnostic testing market with current trends and future estimations to elucidate the imminent investment pockets
  • The report provides a quantitative analysis from 2016 to 2023 to enable the stakeholders to capitalize on prevailing market opportunities
  • Extensive analysis by technology and application helps understand various trends and prevailing opportunities in the respective market
  • Comprehensive analysis of all geographical regions is provided, which determines the main opportunities in these geographies
  • Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which predict the competitive outlook of the market

Immunoprotein Diagnostic Testing Market Key Segment:

By Technology

  • Radioimmunoassay
  • Immunoturbidity Assay
  • Chemiluminescence Assay
  • Immunoprotein Electrophoresis
  • Enzyme-Based Immunoassay
  • Immunofluorescence Assay
  • Others

By Type

  • C-reactive Protein Diagnostic Test
  • Complement System Protein Diagnostic Test
  • Prealbumin Diagnostic Test
  • Haptoglobin Diagnostic Test
  • Immunoglobulin Diagnostic Test
  • Free Light Chain Diagnostic Test
  • Others

By Application

  • Autoimmune Testing
  • Infectious Disease Testing
  • Allergy Testing
  • Endocrine Testing
  • Oncology Testing
  • Toxicology Testing
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENT
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTER’S FIVE FORCES ANALYSIS

3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry

3.4. MARKET SHARE ANALYSIS, 2016
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Increase in geriatric population and surge in incidence and prevalence of chronic diseases
3.5.1.2. Increase in government expenditure in the healthcare sector

3.5.2. Restraint

3.5.2.1. Complex regulatory framework

3.5.3. Opportunity

3.5.3.1. Lucrative opportunities from emerging economies

Chapter: 4 IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. RADIOIMMUNOASSAY

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. IMMUNOTURBIDITY ASSAY

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. CHEMILUMINESCENCE ASSAY

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. IMMUNOPROTEIN ELECTROPHORESIS

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

4.6. ENZYME-BASED IMMUNOASSAY

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast

4.7. IMMUNOFLUORESCENCE ASSAY

4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast

4.8. OTHER TECHNOLOGY

4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast

Chapter: 5 IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. C-REACTIVE PROTEIN DIAGNOSTIC TEST

5.2.1. Market size and forecast

5.3. COMPLEMENT SYSTEM PROTEIN DIAGNOSTIC TEST

5.3.1. Market size and forecast

5.4. PREALBUMIN DIAGNOSTIC TEST

5.4.1. Market size and forecast

5.5. HAPTOGLOBIN DIAGNOSTIC TEST

5.5.1. Market size and forecast

5.6. IMMUNOGLOBULIN DIAGNOSTIC TEST

5.6.1. Market size and forecast

5.7. FREE LIGHT CHAIN DIAGNOSTIC TEST

5.7.1. Market size and forecast

5.8. OTHER IMMUNOPROTEIN DIAGNOSTIC TEST

5.8.1. Market size and forecast

Chapter: 6 IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. AUTOIMMUNE TESTING

6.2.1. Market size and forecast

6.3. INFECTIOUS DISEASE TESTING

6.3.1. Market size and forecast

6.4. ALLERGY TESTING

6.4.1. Market size and forecast

6.5. ENDOCRINE DISEASE TESTING

6.5.1. Market size and forecast

6.6. ONCOLOGY TESTING

6.6.1. Market size and forecast

6.7. TOXICOLOGY TESTING

6.7.1. Market size and forecast

6.8. OTHERS

6.8.1. Market size and forecast

Chapter: 7 IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S. market size and forecast
7.2.5. Canada market size and forecast
7.2.6. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany market size and forecast
7.3.5. France market size and forecast
7.3.6. UK market size and forecast
7.3.7. Italy market size and forecast
7.3.8. Spain market size and forecast
7.3.9. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.4. Japan market size and forecast
7.4.5. China market size and forecast
7.4.6. India market size and forecast
7.4.7. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Latin America market size and forecast
7.5.5. Middle East market size and forecast
7.5.6. Africa market size and forecast

Chapter: 8 COMPANY PROFILES

8.1. ABBOTT LABORATORIES

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. ABCAM PLC

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. BIO-RAD LABORATORIES, INC.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. DANAHER CORPORATION

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segment
8.4.4. Product portfolio
8.4.5. Business performance

8.5. DIASORIN S.P.A

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. ENZO BIOCHEM, INC.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Operating business segments
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. F. HOFFMANN-LA ROCHE AG (ROCHE DIAGNOSTICS)

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. ORTHO CLINICAL DIAGNOSTICS

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Key strategic moves and developments

8.9. SIEMENS AKTIENGESELLSCHAFT

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating segments
8.9.4. Product portfolio
8.9.5. Business performance

8.10. THERMO FISHER SCIENTIFIC INC

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

LIST OF TABLES

TABLE 1. GLOBAL INCIDENCE RATES OF DISEASES
TABLE 2. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 3. RADIOIMMUNOASSAY BASED IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 4. IMMUNOTURBIDITY ASSAY BASED IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 5. CHEMILUMINESCENCE ASSAY BASED IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 6. IMMUNOPROTEIN ELECTROPHORESIS BASED IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 7. ENZYME IMMUNOASSAY BASED IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 8. IMMUNOFLUORESCENCE ASSAY BASED IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 9. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR OTHER TECHNOLOGY, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 10. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 11. C-REACTIVE PROTEIN DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 12. COMPLEMENT SYSTEM PROTEIN DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 13. PREALBUMIN DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 14. HAPTOGLOBIN DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 15. IMMUNOGLOBULIN DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 16. FREE LIGHT CHAIN DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 17. OTHER IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 18. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 19. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 20. INFECTIOUS DISEASES CAUSED BY SPECIFIC HOSTS
TABLE 21. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 22. TYPES OF ALLERGY AND THEIR PREVALENCE
TABLE 23. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ALLERGY, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 24. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ENDOCRINE DISEASES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 25. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ONCOLOGY, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 26. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR TOXICOLOGY TESTING, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 27. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 28. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 29. NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 30. NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 31. NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 32. NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 33. EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 34. EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 35. EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 36. EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 37. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 38. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 39. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 40. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 41. LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 42. LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 43. LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 44. LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 45. ABBOTT: COMPANY SNAPSHOT
TABLE 46. ABBOTT: OPERATING SEGMENTS
TABLE 47. ABBOTT: PRODUCT PORTFOLIO
TABLE 48. ABCAM: COMPANY SNAPSHOT
TABLE 49. ABCAM: OPERATING SEGMENTS
TABLE 50. ABCAM: OPERATING SEGMENTS
TABLE 51. BIO-RAD: COMPANY SNAPSHOT
TABLE 52. BIO-RAD: OPERATING SEGMENTS
TABLE 53. BIO-RAD: PRODUCT PORTFOLIO
TABLE 54. DANAHER: COMPANY SNAPSHOT
TABLE 55. DANAHER: OPERATING SEGMENTS
TABLE 56. DANAHER: PRODUCT PORTFOLIO
TABLE 57. DIOSORIN: COMPANY SNAPSHOT
TABLE 58. DIOSORIN: OPERATING SEGMENTS
TABLE 59. DIOSORIN: PRODUCT PORTFOLIO
TABLE 60. ENZO: SNAPSHOT
TABLE 61. ENZO: OPERATING SEGMENTS
TABLE 62. ENZO: PRODUCT PORTFOLIO
TABLE 63. ROCHE: COMPANY SNAPSHOT
TABLE 64. ROCHE: OPERATING SEGMENT
TABLE 65. ROCHE: PRODUCT PORTFOLIO
TABLE 66. ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 67. ORTHO CLINICAL DIAGNOSTICS: OPERATING SEGMENTS
TABLE 68. ORTHO CLINICAL DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 69. SIEMENS: COMPANY SNAPSHOT
TABLE 70. SEIMENS: OPERATING SEGMENTS
TABLE 71. SIEMENS: PRODUCT PORTFOLIO
TABLE 72. THERMO FISHER: COMPANY SNAPSHOT
TABLE 73. THERMO FISHER: OPERATING SEGMENTS
TABLE 74. THERMO FISHER: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023
FIGURE 2. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023
FIGURE 3. MARKET SEGMENTATION
FIGURE 4. TOP INVESTMENT POCKETS
FIGURE 5. TOP WINNING STRATEGIES, 2014-2016 (%)
FIGURE 6. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 7. MARKET SHARE ANALYSIS, 2016
FIGURE 8. INCIDENCE RATE OF CHRONIC DISEASES, 1995-2030
FIGURE 9. U.S. HEALTHCARE EXPENDITURE PER PERSON (USD)
FIGURE 10. RISING GDP OF MANY COUNTRIES ($TRILLION)
FIGURE 11. NUMBER OF DIAGNOSED CANCER CASES WORLDWIDE
FIGURE 12. GLOBAL COMMON CANCER STATISTICS, 2012-2030
FIGURE 13. SPECIFIC ILLICIT DRUG DEPENDENCE OR ABUSE IN THE U.S., 2013
FIGURE 14. U.S. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 15. CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 16. MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 17. GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 18. FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 19. UK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 20. ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 21. SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 22. REST OF EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 23. JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 24. CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 25. INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 26. REST OF ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 27. LATIN AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 28. MIDDLE EAST IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 29. AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 30. ABBOTT: REVENUE, 2014-2016 ($MILLION)
FIGURE 31. ABBOTT: REVENUE BY SEGMENT, 2016 (%)
FIGURE 32. ABBOTT: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 33. ABCAM: REVENUE, 2014-2016 ($MILLION)
FIGURE 34. ABCAM: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 35. BIO-RAD: REVENUE, 2014-2016 ($MILLION)
FIGURE 36. BIO-RAD: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 37. BIO-RAD: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 38. DANAHER: REVENUE, 2014-2016 ($MILLION)
FIGURE 39. DANAHER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 40. DANAHER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 41. DIOSORIN: REVENUE, 2013-2015 ($MILLION)
FIGURE 42. DIOSORIN: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 43. ENZO: REVENUE, 2014-2016 ($MILLION)
FIGURE 44. ENZO: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 45. ENZO: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 46. ROCHE: REVENUE, 2014-2016 ($MILLION)
FIGURE 47. ROCHE: REVENUE BY SEGMENT, 2016 (%)
FIGURE 48. ROCHE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 49. SIEMENS: REVENUE, 2014-2016 ($MILLION)
FIGURE 50. SIEMENS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 51. SIEMENS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 52. THERMO FISHER: REVENUE, 2014-2016 ($MILLION)
FIGURE 53. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 54. THERMO FISHER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

 

Immunoprotein diagnostic testing is the procedure for analyzing the level of protein for the detection of disease such as infections, cancer, cardiovascular diseases, and others. There are different technologies used for immunoprotein diagnostic, such as radioimmunoassay, immunoturbidity assay, chemiluminescence assay, immunoprotein electrophoresis, enzyme-based immunoassay, immunofluorescence assay, and others. Enzyme-based immunoassays dominated the marked in 2016 owing to high usage for the detection of cancer, POC IVD testing, infectious disease testing, therapeutic drug level monitoring, and the introduction of novel biomarkers. Advanced ELISA second generation technology is used in blood banks, runs on semi-automatic systems, and provides results within 3-4 hours.

North America held the highest share owing to the developed healthcare system, presence of leading diagnostic product manufacturers, higher adoption of advanced and efficient diagnostic products, heavy inflow of investment in proteomics research & drug development, and surge in the number of patients with viral infections and cancer in the region. Asia-Pacific has the highest market potential due to rise in incidence of cancer, growth in per capita income in many countries such as India and China, government initiatives for the improvement of healthcare sector, and rise in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market. Major companies involved in the immunoprotein diagnostic testing market are Siemens Healthcare, Roche Diagnostics Abbott Laboratories, Danaher Corporation, and others.

 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 

Get More Information About This Report

For any queries about purchasing this report, Please fill the form below:

Please input the above text in the input box or click refresh

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts